Molecular Products Group India Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 24-06-2024
- Paid Up Capital ₹ 3.95 M
as on 24-06-2024
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -43.24%
(FY 2020)
- Profit -113.76%
(FY 2020)
- Ebitda -164.25%
(FY 2020)
- Net Worth -4.36%
(FY 2020)
- Total Assets -58.50%
(FY 2020)
About Molecular Products Group India
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 3.95 M, as per Ministry of Corporate Affairs (MCA) records.
Vikrant Patil, Kelly Reinke, Brandon Smith, and One other member serve as directors at the Company.
- CIN/LLPIN
U74120MH2016FTC271967
- Company No.
271967
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
12 Jan 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Molecular Products Group India?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikrant Patil  | Director | 12-Jan-2016 | Current |
Kelly Reinke  | Director | 26-May-2023 | Current |
| Brandon Smith | Director | 26-May-2023 | Current |
Jan Radstaak  | Director | 03-Jun-2021 | Current |
Financial Performance of Molecular Products Group India.
Molecular Products Group India Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 43.24% decrease. The company also saw a substantial fall in profitability, with a 113.76% decrease in profit. The company's net worth dipped by a decrease of 4.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Molecular Products Group India?
In 2020, Molecular Products Group India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Multisorb Technologies India Private LimitedActive 10 years 9 monthsJan Radstaak is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Molecular Products Group India?
Unlock and access historical data on people associated with Molecular Products Group India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Molecular Products Group India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Molecular Products Group India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
